m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00435)
Target Name TNF receptor-associated factor 1 (TRAF1)
Synonyms
Epstein-Barr virus-induced protein 6; EBI6
    Click to Show/Hide
Gene Name TRAF1
Chromosomal Location 9q33.2
Function
Adapter molecule that regulates the activation of NF-kappa-B and JNK. Plays a role in the regulation of cell survival and apoptosis. The heterotrimer formed by TRAF1 and TRAF2 is part of a E3 ubiquitin-protein ligase complex that promotes ubiquitination of target proteins, such as MAP3K14. The TRAF1/TRAF2 complex recruits the antiapoptotic E3 protein-ubiquitin ligases BIRC2 and BIRC3 to TNFRSF1B/TNFR2.
    Click to Show/Hide
Gene ID 7185
Uniprot ID
TRAF1_HUMAN
HGNC ID
HGNC:12031
Ensembl Gene ID
ENSG00000056558
KEGG ID
hsa:7185
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
TRAF1 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 14 (METTL14) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14
Cell Line MDA-MB-231 Homo sapiens
Treatment: siMETTL14 MDA-MB-231 cells
Control: MDA-MB-231 cells
 GSE81164
Regulation
logFC: -8.04E-01
p-value: 5.72E-05
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary In renal cell carcinoma, overexpression of TNF receptor-associated factor 1 (TRAF1) promotes sunitinib resistance by modulating apoptotic and angiogenic pathways in a METTL14-dependent manner.
Target Regulation Up regulation
Responsed Disease Renal cell carcinoma ICD-11: 2C90
 Disease Info 
Responsed Drug Sunitinib Approved
 Drug Info 
Cell Process RNA stability
Cell apoptosis
In-vitro Model OS-RC-2 Clear cell renal cell carcinoma Homo sapiens CVCL_1626
HUVEC-C Normal Homo sapiens CVCL_2959
786-O Renal cell carcinoma Homo sapiens CVCL_1051
In-vivo Model For the xenograft tumor model, approximately 1 × 106 ccRCC cells suspended in 100 uL PBS were subcutaneously inoculated in the right flank of 5-week-old BALB/c nude mice. For the ccRCC orthotopic implantation model, approximately 1 × 106 ccRCC cells suspended in 30 uL Matrigel were injected under the renal capsule of 5-week-old BALB/c nude mice. After 6 weeks, the anesthetized mice were intraperitoneally injected with D-luciferin (Yeason) and imaged using an in vivo imaging system to detect tumor growth and metastasis. For the lung metastasis model, approximately 5 × 105 ccRCC cells suspended in PBS were injected into the tail vein of 5-week-old mice. After 6-8 weeks, mice were anesthetized and lung metastasis was imaged as above.
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by ALKBH5
Cell Line RPMI-8226 cell line Homo sapiens
Treatment: shALKBH5 RPMI8226 cells
Control: shNC RPMI8226 cells
 GSE180214
Regulation
logFC: -6.91E-01
p-value: 6.11E-06
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary ALKBH5 promoted multiple myeloma cell growth and survival through TNF receptor-associated factor 1 (TRAF1)-mediated activation of NF-Kappa-B and MAPK signaling pathways.
Target Regulation Up regulation
Responsed Disease Multiple myeloma ICD-11: 2A83.1
 Disease Info 
Pathway Response MAPK signaling pathway hsa04010
Cell Process Cell apoptosis
RNA stability
In-vitro Model CAG Plasma cell myeloma Homo sapiens CVCL_D569
RPMI-8226 Plasma cell myeloma Homo sapiens CVCL_0014
U266 (Human multiple myeloma cells)
In-vivo Model 5 × 105 selected cells were injected via the tail vein into 4- to 5-week-old NCG mice.
Multiple myeloma [ICD-11: 2A83]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary ALKBH5 promoted multiple myeloma cell growth and survival through TNF receptor-associated factor 1 (TRAF1)-mediated activation of NF-Kappa-B and MAPK signaling pathways.
Responsed Disease Multiple myeloma [ICD-11: 2A83.1]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Up regulation
Pathway Response MAPK signaling pathway hsa04010
Cell Process Cell apoptosis
RNA stability
In-vitro Model CAG Plasma cell myeloma Homo sapiens CVCL_D569
RPMI-8226 Plasma cell myeloma Homo sapiens CVCL_0014
U266 (Human multiple myeloma cells)
In-vivo Model 5 × 105 selected cells were injected via the tail vein into 4- to 5-week-old NCG mice.
Renal cell carcinoma [ICD-11: 2C90]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary In renal cell carcinoma, overexpression of TNF receptor-associated factor 1 (TRAF1) promotes sunitinib resistance by modulating apoptotic and angiogenic pathways in a METTL14-dependent manner.
Responsed Disease Renal cell carcinoma [ICD-11: 2C90]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Sunitinib Approved
 Drug Info 
Cell Process RNA stability
Cell apoptosis
In-vitro Model OS-RC-2 Clear cell renal cell carcinoma Homo sapiens CVCL_1626
HUVEC-C Normal Homo sapiens CVCL_2959
786-O Renal cell carcinoma Homo sapiens CVCL_1051
In-vivo Model For the xenograft tumor model, approximately 1 × 106 ccRCC cells suspended in 100 uL PBS were subcutaneously inoculated in the right flank of 5-week-old BALB/c nude mice. For the ccRCC orthotopic implantation model, approximately 1 × 106 ccRCC cells suspended in 30 uL Matrigel were injected under the renal capsule of 5-week-old BALB/c nude mice. After 6 weeks, the anesthetized mice were intraperitoneally injected with D-luciferin (Yeason) and imaged using an in vivo imaging system to detect tumor growth and metastasis. For the lung metastasis model, approximately 5 × 105 ccRCC cells suspended in PBS were injected into the tail vein of 5-week-old mice. After 6-8 weeks, mice were anesthetized and lung metastasis was imaged as above.
Sunitinib [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary In renal cell carcinoma, overexpression of TNF receptor-associated factor 1 (TRAF1) promotes sunitinib resistance by modulating apoptotic and angiogenic pathways in a METTL14-dependent manner.
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Renal cell carcinoma ICD-11: 2C90
 Disease Info 
Cell Process RNA stability
Cell apoptosis
In-vitro Model OS-RC-2 Clear cell renal cell carcinoma Homo sapiens CVCL_1626
HUVEC-C Normal Homo sapiens CVCL_2959
786-O Renal cell carcinoma Homo sapiens CVCL_1051
In-vivo Model For the xenograft tumor model, approximately 1 × 106 ccRCC cells suspended in 100 uL PBS were subcutaneously inoculated in the right flank of 5-week-old BALB/c nude mice. For the ccRCC orthotopic implantation model, approximately 1 × 106 ccRCC cells suspended in 30 uL Matrigel were injected under the renal capsule of 5-week-old BALB/c nude mice. After 6 weeks, the anesthetized mice were intraperitoneally injected with D-luciferin (Yeason) and imaged using an in vivo imaging system to detect tumor growth and metastasis. For the lung metastasis model, approximately 5 × 105 ccRCC cells suspended in PBS were injected into the tail vein of 5-week-old mice. After 6-8 weeks, mice were anesthetized and lung metastasis was imaged as above.
References
Ref 1 N(6)-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma. Mol Cancer. 2022 May 10;21(1):111. doi: 10.1186/s12943-022-01549-1.
Ref 2 RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-KappaB and MAPK signaling pathways. Oncogene. 2022 Jan;41(3):400-413. doi: 10.1038/s41388-021-02095-8. Epub 2021 Nov 10.